Antonio Cuneo, MD, St. Anna University Hospital, Ferrara, Italy, explains the impact of complex karyotype on treatment efficacy in chronic lymphocytic leukemia (CLL). Whilst it has been shown that complex karyotype is associated with a poor response to chemoimmunotherapy, the impact of this marker in patients treated with BTK and Bcl-2 inhibitors remains unclear. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.